New drug shows promise for rare breast cancer type in early trial
NCT ID NCT05919108
First seen Nov 01, 2025 · Last updated Jun 13, 2026 · Updated 34 times
Summary
This study tests a drug called neratinib, which blocks a protein that helps cancer cells grow. It is given before usual treatment to 30 people with stage I-III HER2-mutated lobular breast cancer. The goal is to see if it works better than standard hormone therapy at shrinking tumors and improving outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE I BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Baylor College of Medicine
NOT_YET_RECRUITINGHouston, Texas, 77030, United States
Contact
-
Emory University/ Winship Cancer Institute
NOT_YET_RECRUITINGAtlanta, Georgia, 30322, United States
Contact
-
University of Pittsburgh Medical Center
NOT_YET_RECRUITINGPittsburgh, Pennsylvania, 15213, United States
Contact
-
University of Texas, Southwestern
RECRUITINGDallas, Texas, 75390, United States
Contact
Contact Email: •••••@•••••
Contact
-
Vanderbilt University/Ingram Cancer Center
RECRUITINGNashville, Tennessee, 37203, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.